Aibili Logo Association for Innovation and Biomedical Research on Light

Latest Ongoing Projects


Centre for Clinical Trials

A multicenter, patient-masked, safety extension study to evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system [more info]

A 3-month, multicenter, Investigator-Masked, Pilot Study to evaluate the eficacy and safety of Bimatoprost/Timolol fixed combination vs Latanoprost in treatment-Naive patients with Open-Angle Glaucoma at high risk of Glaucomatous progression. [more info]

An evaluation of the Ocular Surface Health in subjects using DuoTrav APS eye drops solution versus Xalacom® eye drops solution [more info]

Centre of Clinical Pharmacology

Elaboração e organização de um processo de Autorização de Introdução no Mercado (AIM) de cápsulas moles de 1000mg de ésteres etílicos do ácido omega – 3 90, compreendendo 460mg de éster etílico do ácido eicosapentanóico (EPA) e 380mg do éster etílico do ácido docosahexanóico (DHA). [more info]

Safety and efficacy of eslicarbazepine acetate (ESL) as adjunctive therapy for partial seizures in elderly patients. [more info]

Efficacy and safety of Eslicarbazepine acetate (BIA 2-093) as monotheraphy for patients with newly diagnosed partial-onset seizures: a double- blind, double-dummy, randomized, active-controlled, parallel- group, multicenter clinical study. [more info]

Centre of New Technologies for Medicine

Evaluation of blood-retinal barrier functional alterations by optical coherence tomography [more info]

Retmarker - Critical Health / MA-Tracker [more info]

Ver + Saúde [more info]

Coimbra Coordinating Centre for Clinical Research

Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy [more info]

Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis® monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy [more info]

Epidemiological study of the prevalence of Age-Related Macular Degeneration in Portugal [more info]

Health Technology Assessment

Pharmacotherapeutic and pharmacoeconomic studies performed to six national pharmaceutical companies [more info]

Coimbra Ophthalmology Reading Centre

Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures [more info]

Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis® monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis® plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy [more info]

Epidemiological study of the prevalence of age-related macular degeneration in Portugal [more info]

Projects by department:

Copyright © 2012 AIBILI   -   Contact Us   -   Site Map   -   Webdesign Glitz Design   -   Programming Bizview